Browse the evidence

Optimizing resistance training prescription variables in hypoxia—specifically using non-full-body routines, multi-joint exercises, 9+ sets/week, and training to non-failure—yields a small but significant strength benefit over normoxic training.

To get the most out of hypoxic training, structure your week to train specific muscle groups separately (non-full-body). Use compound movements (squats, presses), aim for at least 9 sets per muscle group weekly, and crucially, stop 1-2 reps before failure. This specific combination yields better strength results than standard hypoxic training.

Synchronous remote weight management interventions for adults with excess weight (BMI ≥ 27.5 kg/m2) face significant engagement barriers including privacy concerns, time burden, technical issues, and digital exclusion, which can be mitigated by facilitators such as digital competency, tailored feedback, convenience, and professional support.

To succeed with a remote weight management program, prioritize platforms that offer strong privacy protections, ease of use, and professional support. Address technical barriers by ensuring you have reliable internet and basic digital skills. Leverage features like self-monitoring and tailored feedback to maintain engagement, as these are key facilitators identified in the research.

Regular use of fish oil and glucosamine supplements is associated with reduced all-cause and cancer mortality in cancer patients, but this benefit is conditional on having a low Life Essential 8 (LE8) score or a poor cancer prognosis.

If you have cancer, taking fish oil or glucosamine may help reduce your risk of death, but only if your overall cardiovascular health (LE8 score) is below average or your specific cancer type has a poor prognosis. For patients with high cardiovascular health scores or good-prognosis cancers, these supplements did not show a significant mortality benefit in this study. Always consult your oncologist before starting supplements.

The effectiveness of interventions on fiber intake diminishes over time, with higher effects observed at 9-24 months compared to 36 months and beyond.

If you join a dietary program, expect the biggest benefits in the first two years. To maintain these benefits long-term, you need to connect the program's lessons to your daily life and ongoing support systems, as the structured intervention's effect fades after 3 years.

Using a single, universal velocity loss (VL) threshold to prescribe resistance training volume is unreliable and fails to control the actual amount of work completed across individuals.

Do not use a single, fixed velocity loss threshold (like stopping at 20% velocity loss) to dictate your training volume for everyone. The study shows that men, women, and individuals with different personality traits (like emotional stability) perform different numbers of reps to reach the same velocity loss. To control volume accurately, you must individualize the threshold based on sex, training history, and strength levels, or accept that the volume will vary significantly.

Sex, emotional stability, and training history significantly influence the number of repetitions performed to reach a specific velocity loss threshold, making universal thresholds invalid.

When using velocity-based training, account for individual differences. Women tend to perform more reps to reach the same velocity loss than men. Additionally, individuals with higher emotional stability may perform more reps. Adjust your velocity loss targets or volume expectations based on these factors rather than applying a single rule.

Dietary energy density and the proportion of hyper-palatable foods are stronger predictors of ad libitum energy intake than macronutrient composition or gut hormone levels.

To control calories, prioritize foods with lower energy density (more volume for fewer calories) and reduce hyper-palatable combinations (high fat/sugar/sodium). These physical properties drive intake more than the specific macronutrient ratios or hormonal responses.

GIP receptor antagonism, when combined with GLP-1 receptor agonism, produces superior weight loss and glycemic control compared to GLP-1 receptor agonism alone.

Current research indicates that combining a GIP receptor antagonist with a GLP-1 agonist (like the investigational drug AMG133) leads to greater weight loss and better blood sugar control than using a GLP-1 agonist alone. This benefit is seen in clinical trials with sustained effects, though the exact mechanism of the GIP part's contribution to weight loss is not fully understood.

Tirzepatide, a dual GLP-1 and GIP agonist, significantly reduces Obstructive Sleep Apnea (OSA) severity and body weight in patients with moderate-to-severe OSA and obesity, marking the first FDA-approved pharmacotherapy for this condition.

If you have moderate-to-severe sleep apnea and obesity, tirzepatide is a new, FDA-approved option. It is a once-weekly injection that helps you lose significant weight (16-17%) and reduces your sleep apnea severity (AHI) by 20-24 events per hour. While it may cause temporary stomach issues, it offers a dual benefit for both your sleep and metabolic health.

Glucagon-like peptide-1 receptor agonists (GLP-1RAs) reduce major adverse cardiovascular events (MACE) and cardiovascular death in people with type 2 diabetes and established CVD.

GLP-1 receptor agonists are effective medications that reduce heart attack and stroke risk in people with diabetes or existing heart disease. Access is improving but remains a barrier due to cost.

Tirzepatide produces greater magnitude and faster velocity of weight loss compared to semaglutide in real-world clinical practice.

If you are choosing between Tirzepatide and Semaglutide for weight loss, Tirzepatide is associated with losing more weight (approx 4% more on average) and losing it faster in the first year. This is based on real-world data from over 20,000 patients.

Tirzepatide is associated with a lower prevalence of gastrointestinal and systemic adverse events compared to semaglutide, particularly in high responders.

If you are concerned about side effects like nausea or vomiting, Tirzepatide may be better tolerated than Semaglutide in real-world use, especially if you are a 'high responder' to the drug.

Demographic disparities exist in weight loss response to GLP-1RAs, with White and female patients more likely to be high responders, while Black and Hispanic patients are more likely to be minimal responders.

Be aware that real-world data shows White and female patients are more likely to achieve high weight loss with GLP-1RAs, while Black and Hispanic patients are more likely to have minimal weight loss. This highlights the need for personalized treatment strategies.

Sleeve gastrectomy (SG) induces metabolic changes beyond restriction by reducing ghrelin and increasing GLP-1 and GIP, which stimulates insulin release and delays gastric emptying to improve type 2 diabetes.

If you undergo sleeve gastrectomy, your body's hormone production changes to help control blood sugar and hunger, not just because your stomach is smaller. This metabolic shift is a key reason why type 2 diabetes often improves after this specific surgery.

GLP-1 and GIP receptor agonists reduce the composite incidence of death due to cardiovascular events, nonfatal myocardial infarction, and nonfatal stroke in patients with overweight or obesity.

If you have overweight or obesity, GLP-1 and GIP receptor agonists like semaglutide can reduce your risk of cardiovascular events, including death, heart attack, and stroke.

Semaglutide (2.4 mg weekly) produces significant weight loss (mean -14.9%) in non-diabetic adults with obesity, but this efficacy is accompanied by a high incidence of mild-to-moderate gastrointestinal adverse events (nausea, vomiting, diarrhea) that often lead to treatment discontinuation.

Semaglutide 2.4mg weekly is highly effective for weight loss in non-diabetics, but expect significant gastrointestinal side effects like nausea and vomiting, especially during the first 16 weeks. These side effects are usually mild-to-moderate and transient, but they are the main reason people stop treatment. Medical supervision is crucial to manage these risks and monitor for rare but serious issues like pancreatitis.

A domestic synthetic semaglutide product (Quincenta) demonstrates bioequivalence, comparable pharmacokinetics, and a similar safety/tolerability profile to the reference originator product (Ozempic) in healthy volunteers.

This study confirms that a specific domestic version of semaglutide (Quincenta) behaves in the body similarly to the brand-name version (Ozempic) when given as a single 0.5 mg dose to healthy people. It had no adverse effects and was not immunogenic. This supports the safety and interchangeability of this specific domestic product with the originator.

Endoscopic Sleeve Gastroplasty (ESG) is a highly cost-effective, less invasive alternative to surgery for Class I obesity, with an ICER well below willingness-to-pay thresholds.

For Class I obesity, ESG offers a durable, cost-effective alternative to surgery with a favorable safety profile. It is particularly valuable for patients who want more than lifestyle changes but are not candidates for or willing to undergo surgery.

Greater weight loss during treatment is associated with a lower likelihood of discontinuing GLP-1 RA, and weight regain after discontinuation is associated with a higher likelihood of reinitiating treatment.

Your weight loss progress directly impacts your likelihood of staying on GLP-1 RA. Greater weight loss correlates with better adherence, while weight regain after stopping often prompts patients to restart. If you experience a plateau, discuss it with your provider rather than stopping abruptly, as continued use may still offer health benefits.

Moderate or severe gastrointestinal (GI) adverse events during GLP-1 RA treatment are associated with a higher hazard of discontinuation and a lower rate of reinitiation.

GI side effects are a common reason for stopping GLP-1 RA. If you experience moderate or severe GI issues, talk to your provider about management strategies. These side effects are linked to higher discontinuation rates, but they can often be mitigated to help you stay on the medication.

Four months of supervised endurance exercise training significantly reduces circulating leukocyte counts, particularly effector subtypes (CD4+ Teff, NK cells, neutrophils), in patients with metabolic syndrome.

If you have metabolic syndrome, engaging in supervised endurance exercise for 3-4 months can significantly lower your circulating immune cell counts, specifically those linked to inflammation (effector T cells, NK cells, neutrophils). This benefit occurs regardless of whether you choose moderate continuous training or high-intensity intervals, suggesting consistency and duration are key drivers for immune modulation.

Blood pressure reduction from exercise training in MetS patients is conditional on achieving a minimum cumulative exercise duration and lower baseline triglyceride levels.

To lower blood pressure through exercise, you likely need to do more than just 'move'. This study suggests you need to reach a minimum weekly volume (e.g., >100 minutes) and that your baseline triglyceride levels influence how much your blood pressure will drop. If your triglycerides are high, you may need even more volume or different strategies to see BP benefits.

In emerging economies like Vietnam, the rapid expansion of modern retail and increased availability of ultra-processed foods (UPFs) drives a shift toward unhealthy dietary patterns, contributing to rising obesity and diabetes rates.

For policymakers in emerging economies: Simply having traditional markets is not enough. You must actively regulate the expanding modern retail sector (supermarkets/convenience stores) through labeling, marketing restrictions, and fiscal incentives to ensure healthy food remains affordable and accessible compared to ultra-processed options.

Experts prioritize communication, education, and voluntary standards over strict regulatory constraints (like taxes or advertising bans) when designing food environment policies.

Policymakers should not rely solely on education and voluntary standards. To effectively combat the rise of UPFs, they must implement stricter regulatory measures like taxes and marketing restrictions, despite perceived feasibility challenges, as these are proven to be effective in other contexts.